Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 5,271 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

NCT04392154
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
160
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 22, 2026, 4:34 PM EDT
Completed No phase listed Observational

Breast Cancer Lung Late Effects

NCT02725840
View directory record Official record
Conditions
Radiation Injury, Breast Cancer
Interventions
Proton beam radiation therapy., X-ray based radiation therapy, Computed Tomography (CT) Scan, Pulmonary Function Test (PFT)
Radiation · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 3 Interventional

Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD

NCT00228540
View directory record Official record
Conditions
ADHD
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
39
States / cities
Scottsdale, Arizona • Irvine, California • Northridge, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

NCT02494024
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Single dose C2N-8E12, Single dose placebo
Drug
Lead sponsor
C2N Diagnostics
Industry
Eligibility
50 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 22, 2026, 4:34 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996
View directory record Official record
Conditions
Mantle Cell Lymphoma, B Cell Lymphoma
Interventions
Sonrotoclax, Zanubrutinib, Placebo
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

NCT00502242
View directory record Official record
Conditions
Kidney Transplant
Interventions
ramipril
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
24
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

NCT02311582
View directory record Official record
Conditions
Malignant Glioma
Interventions
MK-3475, MRI-guided laser ablation
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 22, 2026, 4:34 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

NCT01239082
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy, Fecal immunochemical test (FIT)
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
50,126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

NCT01014988
View directory record Official record
Conditions
Influenza, Human
Interventions
zanamivir aqueous solution
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

NCT02629861
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
178
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

NCT00391768
View directory record Official record
Conditions
Influenza
Interventions
oseltamivir (Tamiflu®)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 23 Months
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 22, 2026, 4:34 PM EDT
Not listed No phase listed Observational

Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer

NCT01658618
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
HP802-247
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
44
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

NCT00160524
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 22, 2026, 4:34 PM EDT
Active, not recruiting Phase 2 Interventional

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions
SAR447537
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

NCT00764868
View directory record Official record
Conditions
ADHD
Interventions
Lisdexamfetamine Dimesylate (LDX)
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

NCT00684060
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 22, 2026, 4:34 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of the Phased Radio Frequency Ablation System

NCT01693120
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
Medtronic Phased RF Ablation System
Device
Lead sponsor
Medtronic Cardiac Ablation Solutions
Industry
Eligibility
18 Years to 75 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 22, 2026, 4:34 PM EDT
Completed No phase listed Observational

Circulating Tumor Cells in Operative Blood

NCT02150746
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
Peripheral/Central Venous Blood Draw, Peritoneal Wash
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00881361
View directory record Official record
Conditions
Breast Cancer
Interventions
systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy, sentinel lymph node biopsy, therapeutic conventional surgery, ultrasound imaging
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
324
States / cities
Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 232 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

NCT04100096
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Brexpiprazole, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
66
States / cities
Bentonville, Arkansas • Bellflower, California • Beverly Hills, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Not applicable Interventional Results available

CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision

NCT00402246
View directory record Official record
Conditions
Arrhythmia, Tachycardia, Atrial Fibrillation, Ventricular Fibrillation
Interventions
Remote Management, In-Office Care
Other
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
127
States / cities
Mobile, Alabama • Mesa, Arizona • Scottsdale, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2011 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Not applicable Interventional

The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function and Wellness in Older Women

NCT02445560
View directory record Official record
Conditions
Aging
Interventions
Probiotic capsule and Fiber Sachet, Probiotic capsule and Placebo sachet, Placebo capsule and Fiber Sachet, Placebo capsule and Placebo sachet
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Gainesville, Florida • Ocala, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 22, 2026, 4:34 PM EDT
Enrolling by invitation No phase listed Observational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

NCT06262282
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions
mycobacteriophage
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 22, 2026, 4:34 PM EDT
Completed No phase listed Observational Results available

Longitudinal Surveillance Study of the 4-SITE Lead/Header System

NCT01596595
View directory record Official record
Conditions
Primary Prevention of Sudden Cardiac Arrest, Secondary Prevention of Sudden Cardiac Arrest
Interventions
Not listed
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
1,820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
104
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 22, 2026, 4:34 PM EDT